Want to see EDIT full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment, crucial for understanding Editas Medicine's focus on innovation and operational strategy.R&D shows volatile, milestone-driven spikes through 2023 followed by a material and sustained pullback in 2025, while G&A trends down steadily—consistent with active cost containment and lower program-level spending. That lowers near-term cash burn and can extend runway, but it also raises execution risk: reduced R&D likely reflects completed milestones or deliberate trimming that could slow pipeline progress and delay catalysts. Watch upcoming program updates and milestone-related spend to judge whether cuts are prudent savings or a drag on future value creation.
Date | Research and Development | General and Administrative |
|---|---|---|
Jun 30, 2026 | $20.18M | $11.60M |
Mar 31, 2026 | $17.60M | $10.23M |
Dec 31, 2025 | $27.40M | $11.35M |
Sep 30, 2025 | $19.77M | $12.32M |
Jun 30, 2025 | $16.18M | $12.86M |
Mar 31, 2025 | $26.59M | $13.38M |
Dec 31, 2024 | $48.61M | $16.35M |
Sep 30, 2024 | $47.64M | $18.09M |
Jun 30, 2024 | $54.21M | $18.21M |
Mar 31, 2024 | $48.79M | $19.34M |